GORE® CARDIOFORM SEPTAL OCCLUDER
Report
- Report Number
- 2017233-2021-02618
- Event Type
- Injury
- Date Received
- December 18, 2021
- Date of Event
- November 13, 2021
- Report Date
- January 30, 2023
- Manufacturer
- W. L. GORE & ASSOCIATES, INC.
- Product Code
- MLV
- PMA / PMN Number
- P050006
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- UK
- Reporter Occupation
- PHYSICIAN
- Health Professional
- Yes
Narratives
H6, COMPONENT CODE: ADDED IMDRF CODE G07001. H6, HEALTH EFFECT - IMPACT CODE: ADDED IMDRF CODE F12. ACCORDING TO THE GORE® CARDIOFORM SEPTAL OCCLUDER INSTRUCTIONS FOR USE (IFU), ADVERSE EVENTS ASSOCIATED WITH THE USE OF THE OCCLUDER MAY INCLUDE, BUT ARE NOT LIMITED TO: NEW ARRHYTHMIA REQUIRING TREATMENT. WITH THE INFORMATION REPORTED TO GORE THIS INVESTIGATION IS CONSIDERED COMPLETE, THE CAUSE OF THE COMPLAINT WAS UNABLE TO BE DETERMINED. H6, HEALTH EFFECT - CLINICAL CODE: REPLACED FDA CODE 1729 WITH IMDRF CODE E060102. H6, HEALTH EFFECT - IMPACT CODE: REPLACED FDA CODE 4644 WITH IMDRF CODE F2303. H6, MEDICAL DEVICE PROBLEM CODE: REPLACED FDA CODE 2993 WITH IMDRF CODE A24. H6, TYPE OF INVESTIGATION: REPLACED FDA CODES 3331, 4111, 4117, WITH IMDRF CODES B14, B13, B20. H6, INVESTIGATION FINDINGS: REPLACED FDA CODE 213 WITH IMDRF CODE C19. H6, INVESTIGATION CONCLUSIONS: REPLACED FDA CODE 11 WITH IMDRF CODE D15.
THE REVIEW OF THE MANUFACTURING RECORDS VERIFIED THAT THE LOT INVOLVED IN THIS EVENT MET ALL PRE-RELEASE SPECIFICATIONS.
IT WAS REPORTED TO GORE THAT A 25MM GORE® CARDIOFORM SEPTAL OCCLUDER WAS SELECTED TO TREAT A PATENT FORAMEN OVALE. FOLLOWING THE IMPLANT, THE PATIENT WAS REPORTED TO HAVE DEVELOPED ATRIAL FIBRILLATION AND WAS ADMITTED TO HOSPITAL, WHERE SHE RECEIVED MEDICATION AND SUBSEQUENTLY SELF-CARDIOVERTED. HOSPITAL DISCHARGE ENSUED AND THE PATIENT WAS REPORTEDLY DOING WELL.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 1936426 | GORE® CARDIOFORM SEPTAL OCCLUDER | TRANSCATHETER SEPTAL OCCLUDER | MLV | W. L. GORE & ASSOCIATES, INC. |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 52 YR | Female | Required Intervention |